Resources

Pharmaron is thrilled to announce the successful completion of Phase One in the major expansion of our Liverpool Gene Therapy and Biologics CDMO site!

MultiOmic Health Limited (“MOH”), an artificial intelligence (AI)-enabled precision medicine biotechnology company, and BIO4 Campus (“BIO4”), the Republic of Serbia's flagship biotechnology and life sciences hub, today announced the signing of a Memorandum of Understanding (MoU) to explore collaborative opportunities in biomedicine, biotechnology and bioinformatics, with a strong emphasis on AI applications.

Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, announces that it has concluded a positive Type C meeting with the US Food and Drug Administration (FDA) for AT278 in people with both type 1 and type 2 diabetes with high daily insulin needs.

Medicines Discovery Catapult (MDC) and King’s College London (KCL) have been awarded £400,000 funding from The Brain Tumour Charity to develop a groundbreaking new approach to treat glioblastoma, for patient benefit.

Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, has garnered widespread media attention1 this week following a renewed focus on the impact of its Brainomix 360 Stroke technology to improve recovery rates for stroke patients.

SeqOne, a pioneer in AI-driven genomic analysis, today announced it has entered into a definitive agreement to acquire Congenica, the UK company spun out of the prestigious Wellcome Sanger Institute.

Pioneer Group, a specialist in life science infrastructure and venture building, has launched a new Accelerator Programme for early-stage life science companies targeting unmet needs in the management of chronic conditions.

BIA member Charm Therapeutics, co-founded by Nobel laureate David Baker, has raised an $80 million Series B to move its AI-designed cancer drug into the clinic early next year.

Roche’s Genentech unit has handed over $20 million in upfront cash for the license to Omass Therapeutics’ preclinical inflammatory bowel disease (IBD) program.

The fourth edition of the Tech Kickstarter Competition is now open for applications. If you are a seed or early-stage company working on a breakthrough product in life sciences, green tech, or tech/AI, this is your chance to accelerate your tech development.

Coulter Partners successfully completed a search assignment for AstriVax Therapeutics NV and is pleased to announce the placement of Dieter Weinand as Chair of its Board of Directors.

CancerTools.org, a unique non-profit cancer research tool supplier and part of Cancer Research UK, has chosen Discovery Park as the home of their first UK based laboratory, growing their team at the Sandwich Science and Tech campus.

The Cell and Gene Therapy Catapult (CGT Catapult) are absolutely delighted to share that it’s Skills Team has been recognised as one of the 57 exceptional training programmes to receive the prestigious Princess Royal Training Award this year for creating a future-ready workforce for advanced therapies!

Discovery Park today announced the arrival of two pioneering biotech companies to its innovation campus.

Asymchem, has announced a significant expansion of its flow chemistry capabilities at its Sandwich, UK facility.

PHARMExcel is celebrating recognition of TOP UK CRO wholeheartedly as an acknowledgement of its efforts to create a distinctive niche in the Contract Research Organisation (CRO) industry, one which balances the commercial and scientific objectives of the biotech/researcher with the practical clinical trial delivery challenges and positive patient outcomes.

Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce the appointment of Penny Fatato in the newly created position of Global Head of Clinical Operations, based in Philadelphia, Pennsylvania, USA.

This is the first-ever autoimmunity study to evaluate a potential functional cure that targets the antigenic source – the origin of autoimmune disease.

First non-hormonal menopause treatment approved for use in the UK by the MHRA, with early-stage development at Stevenage Bioscience Catalyst

Research conducted by Pioneer Group in collaboration with Beauhurst into the UK life sciences landscape reveals a growing trend of investment into more mature companies.